What Next for AxoGen, Inc. (AXGN) After Forming Bullish Wedge Up?

July 14, 2018 - By Linda Rogers

AxoGen, Inc. (NASDAQ:AXGN) Logo

The stock of AxoGen, Inc. (AXGN) formed an up wedge with $55.39 target or 5.00 % above today’s $52.75 share price. The 7 months wedge indicates low risk for the $2.01 billion company. If the $55.39 price target is reached, the company will be worth $100.60M more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

The stock increased 1.15% or $0.6 during the last trading session, reaching $52.75. About 496,513 shares traded or 18.69% up from the average. AxoGen, Inc. (NASDAQ:AXGN) has risen 194.48% since July 14, 2017 and is uptrending. It has outperformed by 181.91% the S&P500.

Analysts await AxoGen, Inc. (NASDAQ:AXGN) to report earnings on August, 1. They expect $-0.08 EPS, down 33.33 % or $0.02 from last year’s $-0.06 per share. After $-0.11 actual EPS reported by AxoGen, Inc. for the previous quarter, Wall Street now forecasts -27.27 % EPS growth.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Among 5 analysts covering AxoGen (NASDAQ:AXGN), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 7 analyst reports since February 5, 2018 according to SRatingsIntel. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, February 28. As per Tuesday, June 26, the company rating was maintained by Leerink Swann. The firm has “Overweight” rating given on Tuesday, May 1 by Cantor Fitzgerald. The stock has “Market Outperform” rating by JMP Securities on Thursday, March 1. The firm earned “Buy” rating on Friday, March 2 by Lake Street. The stock has “Market Outperform” rating by JMP Securities on Tuesday, May 1.

More news for AxoGen, Inc. (NASDAQ:AXGN) were recently published by: Globenewswire.com, which released: “AxoGen, Inc. Appoints Lisa N. Colleran to Board of Directors” on July 10, 2018. Streetinsider.com‘s article titled: “AxoGen (AXGN) Names Lisa N. Colleran to Board” and published on July 10, 2018 is yet another important article.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $2.01 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.